A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. (Q51495372)
Jump to navigation
Jump to search
scientific article published on 31 August 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. |
scientific article published on 31 August 2016 |
Statements
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I (English)
Eli M Roth
Patrick M Moriarty
Jean Bergeron
Garen Manvelian
Jian Zhao
Marie T Baccara-Dinet
Daniel J Rader
ODYSSEY CHOICE I investigators